The medical science industry is definitely seeing a lot of great impact since the introduction of AI. In fact, at the India AI Summit, I saw a ton of companies that are already integrating AI into this industry. Amongst the crowd, though, there was something that caught my attention, and that was this startup called Molecule AI, which is using AI for drug discovery.
At the summit, I sat down with Somraj Bhattacharjee, head of sales and marketing at Molecule AI, and got to know about exactly how this company uses AI to speed up the process of drug development using AI. Let’s take a look at the insights I got from him during our conversation.
Also Read: M.A.N.A.V. Vision Explained: Why India is betting big on it
First up, Somraj gave me a brief introduction to Molecule AI and explained that the company is primarily into drug discovery using AI. He went further and gave a deep dive, explaining what drug discovery is and how it works. He explained that every medicine is made up of certain molecular combinations of different elements.
Traditionally, it took a lot of time to discover these molecules, as there were a lot of human hours involved. But as per him, using Molecule AI, companies can now predict what combination of molecules works best for certain types of diseases, and now they can innovate and create new molecular combinations, using this technology.
I also wanted to understand how AI works in this case and how Molecule speeds up the overall process. To which Somraj explained this deeply, using the current state of the drug market.
As per him, the primary value proposition for drug manufacturers is when there could be a massive reduction in the life-cycle cost of bringing a medicine to market. Traditionally, finding a new molecule combination took up years of manual testing, which was expensive as well. But he claims that Molecule AI is using AI to compress this in much less time.
He stated that, “The AI is able to predict from data, which we obviously get from the customers or from open-source data points, which allows the AI to predict which combination can be tweaked in a certain way to check for molecular properties.”
The biggest concern in the drug manufacturing industry, when it comes to ethics, is data safety and security. And well, that’s mostly because if a manufacturer does research, and if it goes to somebody sitting in a foreign country, then there is a huge risk of losing intellectual property.
But Somraj explained that in their case, they’ve taken steps to counter this problem, and he claims that the data doesn’t go out anywhere, staying with the maker. He claims that Molecule AI is not deploying any data on the cloud; rather, they’re storing everything “on-premise”
Also Read: India AI Summit 2026: Eros Innovation wants to change how content creators interact with cinema
